Leukotriene receptor antagonists inhibit the cysteinyl leukotriene receptors. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Cysteinyl leukotrienes are also released from the nasal mucosa following allergen exposure leading to symptoms associated with allergic rhinitis.

**INDICATION(S):** Relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis

*NO Step Therapy is needed for use in Asthma as long as one other asthma medication is being used.*

**REASONS FOR Step Therapy:**
- ☑ Cost
- □ Potential for misuse
- □ Toxicity

**CRITERIA for APPROVAL:** The patient has had a 30 day trial and FAILURE of Montelukast requires RX claims history

**REASON for DENIAL of BENEFIT:** Patient does not meet above criteria

**BENEFIT APPROVAL:** Approval for a two year

**References:**